Biliary Tract Cancers Btcs Epidemiology Forecast

DelveInsight's "Biliary Tract Cancer (BTC)- Epidemiology Forecast-2032" report delivers an in-depth understanding of the Biliary Tract Cancer (BTC), historical and forecasted epidemiology as well as the Biliary Tract Cancer (BTC) trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Biliary Tract Cancer Understanding

Biliary tract cancers (BTC) constitute epithelial malignancies of the biliary tree and include the following: Gallbladder cancer (GBC) and Cholangiocarcinoma (CCA). CCA is further divided into intra-hepatic CCA, perihilar (Klatskin’s tumor), and distal CCA. Gallbladder cancer is a rare disease in which malignant (cancer) cells are found in the tissues of the gallbladder. It originates in the cells of the gallbladder and most are adenocarcinomas, which begin in the gland cells of the gallbladder lining. Cholangiocarcinoma is a type of cancer that develops within the bile duct system, which is a series of small tubes that transport bile fluid from the liver (where it is produced) to the gallbladder (where it is stored).

 

The signs and symptoms of Biliary Tract Cancer may include pruritus, abdominal pain, malaise, fatigue, jaundice, fever, and more. The majority of BTC cases develops in the absence of identifiable risk factors, as most cases are sporadic and have no identifiable risk factors. However, several conditions have been linked to carcinogenesis which can include primary sclerosing cholangitis, parasitic infections, intrahepatic biliary stones, Caroli’s disease, and others.

 

Diagnosis

For a definitive diagnosis, patients usually undergo endoscopic retrograde cholangiopancreatography and several procedures named as cytology, brushing, FISH (fluorescence in situ hybridization)-polisomy, biopsy, ultrasonography, choledochoscopy, cholangioscopy, chromoendoscopy, confocal endoscopy, narrow-band imaging. MRI, CT, endoscopic ultrasonography, or 18FDG PET-CT cannot definitively demonstrate the stricture's neoplastic nature.

 

Endoscopic ultrasonography-guided fine-needle aspiration demonstrated good diagnostic performance for discriminating benign versus malignant biliary strictures and without apparent risk of tumor seeding linked with the procedure. As for iCCA, the risk of tumor seeding after transperitoneal biopsy of pCCA is based on limited evidence. The role of FISH-polisomy in detecting CCA in patients with PSC has been questioned by a meta-analysis due to its limited sensitivity. Better markers are therefore required for early CCA detection. In this regard, serum CA19-9 levels can be helpful for the detection of CCA. However, the CA19-9 serum level is biased by elevation due to cholangitis and cholestasis and is undetectable in Lewis-antigen-negative patients.

Biliary Tract Cancer Epidemiology

The epidemiology section provides insights about the historical and current Biliary Tract Cancer patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Biliary Tract Cancer epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

 

In the year 2021, the total number of Biliary Tract Cancer cases was 37,451 in the 7MM which are expected to grow during the study period, i.e., 2019–2032.

 

The disease epidemiology covered in the report provides historical as well as forecasted Biliary Tract Cancer epidemiology [segmented as Total Incident Cases of BTC, Total age-specific cases of BTC, Total stage-specific cases of BTC, Total mutation-specific cases of BTC, and Total treated cases of BTC] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Biliary Tract Cancer Epidemiology

The epidemiology segment also provides the Biliary Tract Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

KOL- Views

To keep up with the current Biliary Tract Cancer patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Biliary Tract Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

Scope of the Report

  • The report covers the descriptive overview of Biliary Tract Cancer, explaining their causes, symptoms, pathophysiology, and diagnosis.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Biliary Tract Cancer.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of Cancer, Total number of cancer cases at risk for Biliary Tract Cancer, Total number of Biliary Tract Cancer cases induced by cancer treatment, Total Severity-specific cases of Biliary Tract Cancer.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Biliary Tract Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Biliary Tract Cancer
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Biliary Tract Cancer Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Biliary Tract Cancer  Epidemiology Segmentation

Key Questions

Epidemiology Insights:

  • What are the disease risk, burden, and regional/ethnic differences of Biliary Tract Cancer?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical Biliary Tract Cancer patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Biliary Tract Cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM concerning the patient population about Biliary Tract Cancer?
  • Out of all 7MM countries, which country would have the highest incident population of Biliary Tract Cancer during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Biliary Tract Cancer Disease market
  • To understand the future market competition in the Biliary Tract Cancer Disease market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Biliary Tract Cancer  Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for the Biliary Tract Cancer  Disease market
  • To understand the future market competition in the Biliary Tract Cancer Disease market

1. Key Insights

2. Report Introduction

3. Biliary Tract Cancer (BTC) Market Overview at a Glance

3.1. Drug-class Share (%) Distribution of BTC in 2019

3.2. Drug-class Share (%) Distribution of BTC in 2032

4. Executive Summary of Biliary Tract Cancer (BTC)

4.1. Key Events

5. Epidemiology and Market Methodology

6. Disease Background and Overview

6.1. Introduction

6.2. Classification of Biliary Tract Cancer (BTC)

6.3. Staging

6.3.1. Intrahepatic CCA

6.3.2. Perihilar CCA

6.3.3. Distal Extrahepatic CCA

6.3.4. Gall Bladder Cancer

6.4. Signs and Symptoms

6.5. Causes and Risk Factors

6.6. Pathophysiology

6.7. Genetic Findings in BTC

6.8. Biomarkers

7,. Diagnosis of Biliary Tract Cancer

7.1. Diagnosis

7.1.1. Diagnosis of iCCA

7.1.2. Diagnosis of pCCA and dCCA

7.1.3. Diagnosis of Gall Bladder Cancer

7.2. Diagnostic Algorithm

7.3. Differential diagnosis

7.4. Diagnostic Guidelines

7.4.1. Diagnostic guidelines by The International Liver Cancer Association (ILCA) for iCCA

7.4.2. ESMO clinical practice guidelines for Biliary Tract Cancer

7.4.3. SEOM clinical guidelines for biliary tract cancer

8. Current Treatment Practices of Biliary Tract Cancer

8.1. Treatment of Biliary Tract Cancer

8.1.1. Treatment Algorithm

8.2. Treatment Guidelines

8.2.1. The British Society of Gastroenterology guidelines on the management of cholangiocarcinoma (CCA)

8.2.2. International Liver Cancer Association (ILCA) on the Management of iCCA

8.2.3. ESMO Clinical Practice Guidelines for Treatment and Follow-up for Biliary Tract Cancer

8.2.4. NCCN Guidelines for Hepatobiliary Cancer 2020

9. Epidemiology and Patient Population

9.1. Key Findings

9.2. Assumption and Rationale

9.3. Epidemiology Scenario in the 7MM

9.3.1. Total Incident Cases of Biliary Tract Cancer (BTC) in the 7MM

9.4. Epidemiology Scenario in the United States

9.4.1. Total Incident Cases of Biliary Tract Cancer (BTC) in the United States

9.4.2. Age-specific Cases of Biliary Tract Cancer (BTC) in the United States

9.4.3. Mutation-specific Cases of Biliary Tract Cancer (BTC) in the United States

9.4.4. Stage-specific Cases of Biliary Tract Cancer (BTC) in the United States

9.4.5. Total Treated Cases of Biliary Tract Cancer (BTC) by line of therapies in the United States

9.5. Epidemiology Scenario in EU-5

9.5.1. Total Incident Cases of Biliary Tract Cancer (BTC) in EU-5

9.5.2. Age-specific Cases of Biliary Tract Cancer (BTC) in EU-5

9.5.3. Mutation-specific Cases of Biliary Tract Cancer (BTC) in EU-5

9.5.4. Stage-specific Cases of Biliary Tract Cancer (BTC) in EU-5

9.5.5. Total Treated Cases of Biliary Tract Cancer (BTC) by line of therapies in EU-5

9.6. Epidemiology Scenario in Japan

9.6.1. Total Incident Cases of Biliary Tract Cancer (BTC) in Japan

9.6.2. Age-specific Cases of Biliary Tract Cancer (BTC) in Japan

9.6.3. Mutation-specific Cases of Biliary Tract Cancer (BTC) in Japan

9.6.4. Stage-specific Cases of Biliary Tract Cancer (BTC) in Japan

9.6.5. Total Treated Cases of Biliary Tract Cancer (BTC) by line of therapies in Japan

10. Patient Journey

11. Unmet Needs

12. Appendix

12.1. Bibliography

12.2. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

15. About DelveInsight

List of Tables

Table 1: Summary of Biliary Tract Cancer, Market, Epidemiology, and Key Events (2019–2032)

Table 2: TNM and AJCC/UICC Staging Systems for iCCA

Table 3: AJCC staging of iCCA

Table 4: TNM and AJCC/UICC Staging Systems for pCCA

Table 5: TNM and AJCC/UICC Staging Systems for Perihilar and Distal CCA

Table 6: TNM and AJCC/UICC Staging Systems for pCCA

Table 7: TNM and AJCC/UICC Staging Systems for Gall Bladder Cancer

Table 8: Risk Factors for Biliary Tract Cancer

Table 9: Host Genetic Polymorphism Associated With Cholangiocarcinoma

Table 10: Grading of evidence and recommendations (adapted from GRADE system)

Table 11: Recommendations of iCCA for Diagnosis

Table 12: Recommendations of the British Society of Gastroenterology guidelines

Table 13: Recommendations of iCCA for management

Table 14: NCCN Guidelines for Hepatobiliary Cancer 2020

Table 15: 18 NCCN Guidelines for Principles of Systemic Therapy

Table 16: Total Incident Cases of Biliary Tract Cancer in the 7MM (2019–2032)

Table 17: Total Incident Cases of Biliary Tract Cancer in the US (2019–2032)

Table 18: Age specific cases of BTC in the US (2019–2032)

Table 19: Mutation specific case of BTC in the US (2019–2032)

Table 20: Total BTC cases by stage in the US (2019–2032)

Table 21: Total Treated cases of BTC by line of therapies in the US (2019–2032)

Table 22: Total Incident Cases of Biliary Tract Cancer in EU-5 (2019–2032)

Table 23: Age specific cases of BTC in EU-5 (2019–2032)

Table 24: Mutation specific case of BTC in EU-5 (2019–2032)

Table 25: Total BTC cases by stage in EU-5 (2019–2032)

Table 26: Total Treated cases of BTC by line of therapies in EU-5 (2019–2032)

Table 27: Total Incident Cases of Biliary Tract Cancer in Japan (2019–2032)

Table 28: Age specific cases of BTC in Japan (2019–2032)

Table 29: Mutation specific case of BTC in Japan (2019–2032)

Table 30: Total BTC cases by stage in Japan (2019–2032)

Table 31: Total Treated cases of BTC by line of therapies in Japan (2019–2032)

List of Figures

Figure 1: Epidemiology and Market Methodology

Figure 2: Cholangiocarcinoma subtypes

Figure 3: Classification of Biliary Tract Cancer

Figure 4: Clinical Presentations of Biliary Tract Cancer

Figure 5: Possible Risk Factors And Symptoms

Figure 6: Risk Factors and Molecular Alterations of BTC

Figure 7: Cells of Origin in Cholangiocarcinoma (CCA)

Figure 8: Diagnostic algorithm for iCCA

Figure 9: Diagnostic algorithm for pCCA and dCCA

Figure 10: Differential diagnosis of BTC

Figure 11: Algorithm for diagnosis and management of Biliary Tract Cancer

Figure 12: A suggested algorithm for the diagnosis and treatment of CCA

Figure 13: A suggested treatment algorithm for patients with iCCA

Figure 14: Algorithm for diagnosis and management of dCCA

Figure 15: Flowchart – Management and treatment of patients suspected of perihilar CCA

Figure 16: A suggested diagnosis and treatment algorithm for Gallbladder Cancer

Figure 17: Total Incident Cases of Biliary Tract Cancer in the 7MM (2019–2032)

Figure 18: Total Incident Cases of Biliary Tract Cancer in the United States (2019–2032)

Figure 19: Age specific cases of BTC in the United States (2019–2032)

Figure 20: Mutation specific cases of BTC in the United States (2019–2032)

Figure 21: Total BTC cases by stage in the United States (2019–2032)

Figure 22: Total Treated Cases of Biliary Tract Cancer by line of therapies in the United States (2019–2032)

Figure 23: Total Incident Cases of Biliary Tract Cancer in EU-5 (2019–2032)

Figure 24: Age specific cases of BTC in EU-5 (2019–2032)

Figure 25: Mutation specific cases of BTC in EU-5 (2019–2032)

Figure 26: Total BTC cases by stage in EU-5 (2019–2032)

Figure 27: Total Treated Cases of Biliary Tract Cancer by line of therapies in EU-5 (2019–2032)

Figure 28: Total Incident Cases of Biliary Tract Cancer in Japan (2019–2032)

Figure 29: Age specific cases of BTC in Japan (2019–2032)

Figure 30: Mutation specific cases of BTC in Japan (2019–2032)

Figure 31: Total BTC cases by stage in Japan (2019–2032)

Figure 32: Total Treated Cases of Biliary Tract Cancer by line of therapies in Japan (2019–2032)

Forward to Friend

Need A Quote